Mandate

Vinge advises Industrifonden in connection with its investment in solar cells company, Sol Voltaics

July 04, 2011

Vinge has advised Stiftelsen Industrifonden in connection with its SEK 18.5 million investment in the solar cells company, Sol Voltaics. Sol Voltaics has developed a completely new type of material which can significant reduce the cost of producing electricity from solar cells. The total amount of the issue is SEK 40 million and the capital will be used for the future development of the company’s products. Sol Voltaics has developed a new material and a new production method for the manufacture of solar cells. In brief, it is based upon the rapid production of nano threads of gallium arsenide (GaAs), where each thread is a solar cell. This material has been widely recoginsed for some time as the best way of manufacturing solar cells although up to now it has been too expensive to use. Sol Volatics has now developed a method which can radically reduce the costs associated with the aforementioned method.

Vinge’s team consisted of Johan Larsson (project manager) and Claes Henriksson. Johan Winnerblad was the responsible partner.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026